2025-08-28 23:20:37
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Samrat Pharmachem Q3FY22 PAT zooms to Rs. 6.44 crores
Posted On : 2022-02-10 18:15:06( TIMEZONE : IST )
SAMRAT PHARMACHEM LTD. has reported Standalone financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 55.5781 crores during the period ended December 31, 2021 as compared to Rs. 59.1487 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 6.4469 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 2.7895 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 20.87 for the period ended December 31, 2021 as compared to Rs. 9.03 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 55.5781 crs | ₹59.1487 crs |  -6.04% |
| Net Profit | ₹6.4469 crs | ₹2.7895 crs |  131.11% |
| EPS | ₹20.87 | ₹9.03 | 131.12% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 55.5781 crores during the period ended December 31, 2021 as compared to Rs.54.9410 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.6.4469 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.1.5359 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.20.87 for the period ended December 31, 2021 as compared to Rs.4.97 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 55.5781 crs | ₹54.9410 crs | 1.16% |
| Net Profit | ₹6.4469 crs | ₹1.5359 crs | 319.75% |
| EPS | ₹20.87 | ₹4.97 | 319.92% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.162.1186 crores during the 9 Months period ended December 31, 2021 as compared to Rs.131.7468 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.10.1902 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.3.7734 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.32.98 for the 9 Months period ended December 31, 2021 as compared to Rs.12.21 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹162.1186 crs | ₹131.7468 crs | 23.05% |
| Net Profit | ₹10.1902 crs | ₹3.7734 crs | 170.05% |
| EPS | ₹32.98 | ₹12.21 | 170.11% |
Shares of SAMRAT PHARMACHEM LTD. was last trading in BSE at Rs. 480.20 as compared to the previous close of Rs. 465.70. The total number of shares traded during the day was 6507 in over 218 trades.
The stock hit an intraday high of Rs. 484.95 and intraday low of 442.45. The net turnover during the day was Rs. 2990353.00.
